Important Safety Information

Do not use Renvela if you have a history of bowel obstruction. Talk to your doctor if you have had difficulty swallowing or swallowing disorders; or if you have had digestive tract surgery or other digestive disorders, including severe constipation. View Important Safety Information.

Diet and Lifestyle Tips to Help Keep Your Minerals in Balance

Maintaining the right levels of phosphorus, calcium, and parathyroid hormone (PTH) is an important goal of your healthcare team—but they need your help! There are many ways you can stay in control and in balance.

  • Go to dialysis. Never miss or leave early from your scheduled dialysis session.
  • Stick to a low-phosphorus diet. Dialysis helps remove some of the extra phosphorus in your blood, but not all of it. So it’s important to cut down on the amount of phosphorus you eat. Your dietitian can help you plan healthy, low-phosphorus meals and snacks. Follow the diet you and your dietitian put together.
  • Manage your calcium intake. Your dietitian may also want you to watch how much calcium you’re getting. Be sure to follow your dietitian’s recommendations.
  • Take the phosphate binder prescribed by your doctor. You can’t get rid of all of the phosphorus in your diet, so phosphate binders are often prescribed to help clear away the phosphorus you do eat. Taken with meals and snacks1,2, phosphate binders soak up and hold on to (or “bind”) the phosphorus found in the foods you eat. They then carry that phosphorus out of the body through your digestive system. Make sure to take your phosphate binder as directed. Do not skip doses.
  • Know your number. Ask your doctor what your phosphorus goal is. As a general rule, the target phosphorus level for patients on dialysis is 2.5 mg/dL to 4.5 mg/dL.3 A regular blood test can check this number and help make sure your phosphorus is under control.

Indication for Renvela

Renvela (sevelamer carbonate) is used to control phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Download Diet and Lifestyle Tips to Help You Manage Your CKD

Contact Us

Genzyme Therapeutics
500 Kendall Street
Cambridge, MA 02142

Tel: 617-768-9000
Fax: 617-252-7600
Toll free: 800-847-0069

Contact Genzyme

Indication

Renvela (sevelamer carbonate) is used to control phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Important Safety Information

  • Do not use Renvela if you have a history of bowel obstruction
  • Talk to your doctor if you have had difficulty swallowing or swallowing disorders; or if you have had digestive tract surgery or other digestive disorders, including severe constipation
  • Uncommon cases of bowel obstruction and perforation have been reported. Your doctor should monitor bicarbonate and chloride blood levels. Vitamins D, E, K (clotting factors), and folic acid blood levels should also be monitored by your doctor
  • The most frequently occurring side effects observed with sevelamer carbonate tablets were nausea and vomiting
  • Side effects with sevelamer carbonate powder taken three times a day were similar to those reported for sevelamer carbonate tablets
  • The most common side effects with sevelamer hydrochloride, which contains the same active ingredient as sevelamer carbonate, included: vomiting, nausea, diarrhea, indigestion, abdominal pain, flatulence, and constipation
  • Cases of fecal impaction and, less commonly, slow bowel activity, bowel obstruction, and bowel perforation have been reported
  • Take Renvela with meals and adhere to your prescribed diet
  • Talk to your doctor when taking Renvela with other medications
  • Promptly contact your doctor if you experience severe abdominal pain, new or worsening constipation, or other severe intestinal symptoms while on Renvela

Please see full Prescribing Information (PDF).

References

  1. Delmez J, Block G, Robertson J, et al. A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. Clin Nephrol. 2007;68:386-391.

  2. Data on file, Genzyme Corp.

  3. Kidney Disease: Improving Global Outcomes (KDIGO) CKD–MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD–MBD). Kidney Int. 2009;76(suppl 113):S1-S130.